🚨 Watchlist Update: Multiple Buy Levels Triggered
Three stocks from our Top 10 Breakout Watchlist this week have already cleared their recommended buy levels. Here’s a quick rundown:
Halliburton Company (NYSE: HAL) has broken out of a falling wedge pattern and cleared our buy level of $35.60. The stock closed at $35.62 — holding just above entry after an intraday high of $35.70.
CSX Corporation (NASDAQ: CSX) broke out of a flag pattern and pushed through our buy level of $52.00, closing at $52.27 — with an intraday high of $52.39 on a +1.9% session.
SLB Limited (NYSE: SLB) broke out of a symmetrical triangle pattern and cleared our buy level of $53.50, closing at $54.08 — already a ~1% move above entry, with an intraday high of $54.34.
Bottom line: Use trailing stops to lock in early gains and let the winners run. And now, on to today’s featured setup…
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) just broke out to a fresh 52-week high on a +22.2% single-session surge — and looks headed even higher.
As we’ll get to just ahead, the combination of a blowout quarter that put its flagship heart treatment on track for $1 billion in annual sales, fast-growing adoption with plenty of room left to run, and a fresh technical breakout makes KNSA one of the more interesting setups on the board. Here’s what’s going on…
The Themes Behind the Move
Kiniksa is a London-based biopharmaceutical company built around ARCALYST (rilonacept) — the only FDA-approved treatment for recurrent pericarditis that works by blocking IL-1, an inflammatory signaling protein. Kiniksa sells ARCALYST under a profit-sharing partnership with Regeneron, and it’s developing two wholly owned follow-ups: KPL-387, a once-monthly injection now in a pivotal Phase 3 trial, and KPL-1161, a potentially once-quarterly injection headed into its first human trial.
In plain English, pericarditis is inflammation of the thin sac that surrounds the heart — and for some patients it keeps coming back, bringing sharp chest pain, repeat hospital visits, and long stretches on steroids. ARCALYST is a weekly self-injection that calms the inflammation driving those flare-ups, and patients tend to stay on it for about three years. Kiniksa’s business hinges on how many cardiologists prescribe it, how early in the disease they reach for it, and whether its less-frequently dosed successors can extend the franchise for years to come.
KNSA’s latest move reflects a powerful confluence of developments — commercial, financial, and clinical — that have come together to put ARCALYST on track to become a billion-dollar-a-year product.
| Theme / Catalyst | What Happened | Why Traders Care |
|---|---|---|
| Blowout Q3 + raised full-year guidance | On October 27, 2026, Kiniksa reported Q3 ARCALYST net revenue of $286.0 million (+58% YoY), topping the roughly $260.7 million FactSet consensus. GAAP diluted EPS came in at $0.56 versus $0.35 expected, and net income jumped to $47.3 million from $18.4 million a year earlier. Management also raised FY2026 ARCALYST guidance to $1.045B–$1.050B, up from $980M–$995M. The stock surged +22.23% to close at $89.20, tagging a new 52-week high of $90.80. | A beat on both revenue and earnings plus a $60 million midpoint guidance raise is the cleanest kind of earnings catalyst — it supports upward estimate revisions across the Street. Crossing $1 billion in annual sales would make ARCALYST a “blockbuster,” the industry’s label for a top-tier franchise. (That milestone is guided, not yet booked.) |
| Rapidly expanding adoption | ARCALYST now reaches about 23% of the estimated 14,000 U.S. patients each year whose pericarditis has come back multiple times — up from ~18% at year-end 2025. More than 5,450 physicians have prescribed it since launch (about 450 new prescribers in the quarter), and the average patient stays on therapy for roughly three years. On the earnings call, management highlighted growing use after a patient’s first recurrence (about 20% of prescriptions), a group of roughly 26,000 additional patients a year. Its Heart’s Home awareness campaign has driven a 12-fold jump in website traffic. | More than three-quarters of the core market is still untreated, and the earlier-treatment push could roughly triple the addressable patient pool — a long growth runway. Because patients stay on therapy for years, each new start becomes recurring revenue. (Not every untreated patient is eligible or reachable, so the headroom isn’t all upside.) |
| Sector tailwinds | The American College of Cardiology’s 2025 expert consensus guidance recognizes IL-1 inhibitors for recurrent or persistent pericarditis when first-line therapies fail — and increasingly favors them over steroids in appropriate patients. ARCALYST remains the only FDA-approved IL-1 pathway inhibitor for recurrent pericarditis in the U.S. The broader shift toward targeted biologic therapies, earlier specialist referral, and better disease awareness adds structural demand support. | Cardiology guidance shapes how doctors prescribe — and when it points toward IL-1 blockers, the only approved drug in that class is the natural beneficiary. Standard anti-inflammatory pills remain first-line, so guidance is a tailwind rather than a guarantee of reimbursed prescriptions. |
| Profitable, debt-free, and self-funding its next act | ARCALYST collaboration operating profit rose about 67% YoY to $211.6 million — outpacing revenue growth — before Regeneron’s share under the collaboration agreement. GAAP operating income more than doubled to $54.2 million, lifting operating margin to ~19% from 13.3%. Cash and investments climbed to $568.8 million with zero debt. That cash is funding KPL-387, which posted positive Phase 2 results (median symptom response in four days at the selected monthly dose) and is now enrolling its pivotal Phase 3 trial — the final large-scale study typically needed before seeking approval. | Profit growing faster than sales is the operating-leverage signal traders want. Management expects the business to stay cash-flow positive while funding the pipeline — which sharply reduces dilution risk. A once-monthly shot versus ARCALYST’s weekly injections could also strengthen the franchise’s competitive position for the long haul. |
| Analyst coverage | Based on 12-month price targets from 5 Wall Street analysts over the last three months, the average target sits at $96.40, with a high of $107.00 — implying about 8% upside to the average and ~20% to the top end from the $89.20 close. The broader consensus rating is Strong Buy. Post-earnings, Wedbush raised its target from $99 to $102 (Outperform), following summer raises from JPMorgan ($72 → $107), TD Cowen ($65 → $95), and Goldman Sachs ($75 → $90). | The stock has run right up to the average target — a sign of how fast the price outpaced the Street. Wedbush was the first post-Q3 revision, and more raises would be the natural follow-through if analysts reset models to the new guidance. Our targets are chart-based, so we’re leaning on the technicals here rather than Street targets. |
| Market conviction signal | KNSA’s breakout session came on roughly 2.32 million shares — about four times October 23’s volume and the heaviest print since the late-July gap. Ahead of earnings, options-flow data flagged buying in November and December $90 calls, and short interest stood at about 3.76 million shares (~8–10% of float, ~6–7 days to cover). | A 22% earnings-day move on four times normal volume points to real demand rather than thin-tape drift. Moderate short interest can add fuel if the stock keeps pushing higher — though neither the options flow nor the short position confirms a squeeze, so treat both as supporting evidence rather than the thesis. |
| Upcoming triggers | Traders are watching the targeted start of KPL-1161’s first human trial by year-end 2026, Q4/FY2026 earnings expected in Q1 2027 (date not yet confirmed), pivotal KPL-387 Phase 3 data in H2 2027, and a potential KPL-387 launch in 2028–2029. Kiniksa also promoted Ross Moat to President and COO, effective October 17. | The Q4 report is the next hard test: full-year guidance implies Q4 sales of roughly $301M–$306M, and the first FY2027 outlook will set the tone for 2027 estimates. Pipeline milestones then layer longer-dated catalysts on top of the commercial story. |
If needed, swipe or scroll sideways to view the full table.
Put it all together, and KNSA is looking less like a single-product biotech riding one hot quarter and more like a profitable, debt-free commercial franchise with years of under-penetrated demand ahead of it — and a self-funded pipeline designed to extend that franchise well beyond ARCALYST.
The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.
Bullish Technical Signals
#1 Breakout From Consolidation Area: For roughly three months, KNSA traded inside a well-defined range between ~$72 and ~$84 (marked in purple on the daily chart). That range was a sideways digestion of the late-July gap that lifted the stock out of the mid-$60s. It has now resolved emphatically. The latest session delivered a +22.23% move to close at $89.20 after opening at $85.00, already above the range ceiling, and an intraday dip to $82.26 was bought aggressively on the way to a $90.80 high. The sequence before the breakout matters as much as the breakout itself. Just one session earlier, price slid to the floor of the range near $71 and below the 50-day SMA, a shakeout that flushed weak holders. The stock then traversed the entire box, floor to ceiling and beyond, in a single candle. Volume of 2.32M shares, the heaviest print since the July gap, confirms that this was real demand rather than a thin-tape drift. The former ceiling near $84 now flips to support, which is exactly why the $85 pullback entry sits just above it.
KNSA – Daily Chart
#2 Price Above 50-MA and 200-MA: KNSA now trades above both its 50-day SMA ($78.23) and 200-day SMA ($59.38). The 50-day sits well above the 200-day, so the golden-cross alignment that has defined this entire advance is still intact. The speed of the reclaim stands out: the stock closed below the 50-day the prior session and recovered it with room to spare in one move. The 50-day flattened during the consolidation, which is normal as a base builds. Meanwhile the 200-day kept rising steadily and remains the trend’s structural foundation. Together they create a tiered defense: first the old range ceiling near $84, then the 50-day near $78, then the 200-day near $59. The honest caveat is that after a 22% gap, price sits ~14% above the 50-day and ~50% above the 200-day. That stretch is meaningful, and gaps of this size often get partially retraced. A retest of the $84–$85 breakout zone would be a healthy reset, not a crack in the thesis, and it is the higher-quality entry versus chasing the spike.
#3 Bullish Stochastic: The daily Stochastic delivered a sharp bullish crossover, with %K (blue) vaulting to 92.05 against a %D (orange) reading of 45.86. The location of the cross is what gives it conviction. %K launched from near 20, the lower edge of its range, rather than crossing mid-air, so the momentum shift began from a washed-out base created by the pre-breakout shakeout. The 46-point gap between the lines reflects the violence of the move, and %D will close that gap as its three-period smoothing catches up. %K is already in overbought territory above 80. In a breakout context, however, overbought confirms strength rather than warning of reversal. During the June–July leg higher, KNSA’s Stochastic held above 80 for roughly four weeks while price kept climbing. The practical read is the same as #2: momentum is firmly with buyers, but near-term digestion is likely, which favors buying the dip over the spike.
#4 Bullish MACD: The MACD line (1.08) has crossed above its signal line (0.7338), and the histogram has flipped back to positive at +0.3449. It had turned negative for just a single bar during the shakeout. The backstory makes this cross more meaningful than a routine signal-line flip. After peaking near 4.5 following the July gap, MACD bled steadily back to the zero line through the consolidation. Momentum was unwound by time rather than by price, since the stock surrendered almost none of its gains. A crossover that fires from this reset, near-zero base is the higher-quality variety: it marks a fresh impulse rather than a late-cycle extension of an already-stretched move. Stacked against the Stochastic cross in #3, both momentum reads turned in the same session as the range breakout, so price and momentum are confirming each other.
#5 Bullish Flag Breakout with Price Above 50-MA and 200-MA: Zooming out, the weekly chart reframes the daily range as a textbook bull flag. The “pole” is the near-vertical advance from ~$46 in late spring to ~$83 by late July, the steepest leg of a broader uptrend tracked by the pink trendline since spring 2025. The “flag” is the roughly 12-week pause between ~$73 and ~$81 that followed, and it held nearly all of the pole’s gains. This week’s candle (O $76.00, H $90.80, L $70.67, C $89.20, +16.25%) first undercut the flag’s floor, then reversed to close above its ceiling near the high. A failed breakdown that flips into a breakout is one of the more forceful sequences a chart can produce, because it traps the late sellers who bet on the break lower. The measured move adds a useful cross-check. Projecting the pole’s ~$35–$37 height from the ~$81 flag ceiling points to the high-$110s, which lines up with our $120 second target. Price is also well above its rising 50-week ($56.86) and 200-week ($30.12) SMAs, and with the daily breakout and the weekly flag resolving in the same direction, the signal carries more weight than either timeframe alone. Two points of nuance apply. The weekly bar is still in progress, so a Friday close above ~$81 is what formally confirms the breakout. And at ~57% above its 50-week average, the stock is extended on this timeframe too.
KNSA – Weekly Chart
#6 Bullish ADX and DI: On the weekly, +DI (31.51) leads –DI (7.22) by more than 24 points, so buyers clearly control direction. ADX at 54.63 sits above both lines, confirming the trend has serious strength behind it. The path ADX took to get there is the textbook one: it climbed from below the 20 threshold in spring 2026 to beyond 50, which describes a trend born from a quiet base and accelerating into a dominant one. The flag period adds a telling detail. +DI cooled from its July peak during those 12 sideways weeks, yet –DI kept sliding to just 7, so sellers never gained traction. ADX also kept rising throughout, so the pause did not dent the trend’s underlying force. The caveat is that ADX above 50 is mature, high-strength territory. The early warning to watch is ADX flattening or rolling over, which would signal a slowing trend rather than a reversal. For now, it is still pointing higher.
#7 Bullish Aroon: The weekly Aroon shows the strongest configuration the indicator can print: Aroon Up (orange) at 100% and Aroon Down (blue) at 0%. The way it got there is instructive. Through the flag, Aroon Up decayed steadily from 100 to roughly 35 as the July high aged, which is the mechanical fingerprint of a consolidation. The snap back to 100 means KNSA has just logged a fresh 14-week high, so the breakout is confirmed in Aroon’s terms. Aroon Down tells the other half of the story. It has hugged the floor for most of the past year, and even this week’s shakeout to $70.67 failed to register a new 14-week low. This rounds out the weekly picture: the flag says the trend has resumed, ADX says it is strong, and Aroon says new highs are coming in while new lows are absent.
Risks to Consider
Even strong setups can fail, especially in a single-product commercial biotech like Kiniksa. A few things could knock the stock off course:
- A breakdown back into the former $72–$84 consolidation range on heavy volume would invalidate the breakout thesis
- Negative company-specific news, broader market weakness, or regulatory changes affecting the biotech sector could trigger a sell-off
- Post-earnings overextension — after a 22% one-day jump, KNSA carries a market cap of roughly $6.96 billion, about 6.6x FY2026 guided sales, with a trailing P/E near 67x per market data; much of the growth story is already priced in, and gaps this size are often partially retraced
- Single-product concentration — essentially all product revenue comes from ARCALYST, and under the Regeneron agreement collaboration profits are split roughly 50/50 after specified costs, limiting Kiniksa’s retained economics
- Slowing sequential growth — full-year guidance implies Q4 revenue of about $301M–$306M, just 5–7% sequential growth versus Q3’s ~17.4%, while R&D and commercial spending are set to rise
- Insider selling — a third-party compilation shows roughly $47.8 million in officer and director sales (about 977,000 shares) over the trailing 12 months with no purchases, though about 99% came through pre-arranged trading plans
- Competition from off-label anakinra and investigational IL-1 drugs such as goflikicept could pressure ARCALYST’s market position or pricing, and earlier-treatment adoption depends on physician decisions and insurer coverage
- Pipeline execution — KPL-387’s Phase 2 results don’t guarantee Phase 3 success, pivotal data isn’t due until H2 2027, and KPL-1161 has yet to enter human trials
The Bottom Line
KNSA is breaking out of a three-month consolidation range on the daily chart while resolving a textbook bull flag on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.
The fundamental story underneath the chart is just as strong: Q3 revenue up 58% to $286 million, full-year guidance raised to $1.045B–$1.050B, and $568.8 million in cash with zero debt.
Combine that with multiple catalysts staggered through the next year and beyond — KPL-1161’s first human trial by year-end, Q4 earnings and the first FY2027 outlook in early 2027, and pivotal KPL-387 Phase 3 data in the back half of 2027 — and KNSA looks like one of the more compelling risk-reward setups on the board right now.
If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our two entry options — one on breakout, one on pullback — both price targets that imply 16%–41% potential upside, and the stop-losses we’re using to manage the downside.
Recommended Trade Setup
We’re offering two ways to play KNSA. Case 1 is for traders who want confirmation that the breakout is extending beyond the $90.80 session high. Case 2 is for traders who’d rather wait for a pullback toward the $84–$85 breakout zone — which, as noted in signal #2, is the higher-quality entry after a 22% gap.
Case 1: On Breakout
| Item | Detail |
|---|---|
| Buy Level | Above approximately $91.00 |
| Price Target 1 | $106.00 — Potential upside: 16% |
| Price Target 2 | $120.00 — Potential upside: 32% |
| Timeframe | Next 3–6 months |
| Stop-Loss | $82.00 on a closing basis |
| Trade Invalidation | Void if price hits stop-loss before entry triggers |
If needed, swipe or scroll sideways to view the full table.
For a risk of approximately $9.00 per share, the target rewards are about $15.00 and $29.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.
Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If KNSA drops to or below the $82.00 stop-loss before the $91.00 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.
Case 2: On Pullback
| Item | Detail |
|---|---|
| Buy Level | On pullback to approximately $85.00 |
| Price Target 1 | $106.00 — Potential upside: 25% |
| Price Target 2 | $120.00 — Potential upside: 41% |
| Timeframe | Next 3–6 months |
| Stop-Loss | $74.00 on a closing basis |
If needed, swipe or scroll sideways to view the full table.
For a risk of approximately $11.00 per share, the target rewards are about $21.00 and $35.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.
Happy Trading!
Tara and Greg
🥈 Almost Made the Cut
Today’s featured trade, Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA), was our top pick of several breakout candidates we evaluated. The following two stocks were strong candidates that made it to the final round — they came up just short of the top spot, but remain on our watchlist and could be featured soon:
Johnson Controls International plc (NYSE: JCI) — The building-technology and thermal-management leader is emerging as a key beneficiary of the AI data-center buildout, posting a fiscal Q4 beat, a record $23 billion backlog, 44% organic order growth, and FY2027 guidance for double-digit organic growth. The stock remains in a well-defined long-term uptrend and is consolidating just below its 52-week high — a decisive move above roughly $160 could open the door to the next leg higher.
Tesla, Inc. (NASDAQ: TSLA) — Robotaxi expansion across multiple U.S. cities, rising FSD subscriptions, a surprise positive free-cash-flow quarter, and exploratory SpaceX merger talks keep Tesla at the center of the AI and autonomy story. Shares have reclaimed key moving averages but are now pressing into heavy resistance between roughly $400 and $440 — a clean breakout above that zone would significantly strengthen the setup, while a pullback could offer a better entry.
